Clinuvel Pharmaceuticals Limited (CUVL)

From the record

Clinuvel Pharmaceuticals Limited's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Clinuvel Pharmaceuticals Limited's 3 filed years say what it did: revenue went from $58 million in fiscal 2024 to $64 million in fiscal 2026, up 5.4% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 3 of 3 of those years (its annual reports).

From the record

Over the 2 fiscal years to 2026-06-30, Clinuvel Pharmaceuticals Limited's diluted share count shrank about 0.3% a year, and dividends and buybacks returned about 9% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-06-30, Clinuvel Pharmaceuticals Limited earned about 12 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 26 cents per dollar of everything the company owns. Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count grew 0.7% over the year (the filed statements).

From the record

Clinuvel Pharmaceuticals Limited's standing among 1 graded names in its industry family: revenue of $64 million in fiscal 2026 ranks in the top 50% by size; a net margin of 36% ranks in the top 50%; revenue growth of 5.4% a year over the last 2 filed years ranks in the top 50% (its annual reports).

From the record

Clinuvel Pharmaceuticals Limited's room to grow, from the newest filed statements (fiscal 2026): cash of $14 million against no long-term debt tagged leaves 6.8% of its assets as net cash, top 50% of its family; cash from operations less capital spending is 18.4% of revenue (top 50%); a gross margin of 82.9% (top 50%); research spending of 19% of revenue (top 50%) (its annual report).

From the record

Clinuvel Pharmaceuticals Limited's growth drivers, from the filed years to fiscal 2026: revenue grew 5.4% a year over the last three filed years against 5.4% over all 3, speeding up (top 50% of its family); the newest year grew 5.2% (top 50%); research spending grew 10.6% a year (top 50%); capital spending grew -46.2% a year (top 50%) (its annual reports). Clinuvel Pharmaceuticals Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.